Demographic data
. | Category . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | 1, Persistently negative . | 2, Fluctuating positive . | 3, Persistently positive . | 4, Relapse . | Total . | ||||
| No. patients | 36 | 51 | 27 | 129 | 243 | ||||
| Patient age, y, median | 35.9 | 32.7 | 36.9 | 34.3 | 34.3 | ||||
| Patient sex | |||||||||
| Female | 13 | 20 | 11 | 60 | 104 | ||||
| Male | 23 | 31 | 16 | 69 | 139 | ||||
| Duration of disease before SCT, y | |||||||||
| Overall | 1.16 | 0.86 | 0.76 | 1.16 | 1.07 | ||||
| Siblings | 0.83 | 0.60 | 0.67 | 0.73 | 0.72 | ||||
| Alternate | 2.1 | 1.80 | 1.6 | 1.7 | 1.69 | ||||
| Disease status at transplantation | |||||||||
| CP | 33 | 39 | 24 | 117 | 213 | ||||
| Advanced | 3 | 12 | 3 | 12 | 30 | ||||
| Donor | |||||||||
| Identical sibling | 24 | 33 | 20 | 52 | 129 | ||||
| Alternative | 12 | 18 | 7 | 77 | 114 | ||||
| GvHD prophylaxis | |||||||||
| Non-TCD | 24 | 31 | 20 | 43 | 114 | ||||
| TCD | 12 | 20 | 7 | 86 | 125 | ||||
| Follow-up, mo | |||||||||
| Range | 21-271 | 15-230 | 20-212 | 16-257 | 15-271 | ||||
| Median duration | 125 | 86 | 54 | 77 | 84.3 | ||||
| PCR determinations/patient | |||||||||
| Median no. | 9 | 14 | 20 | 25 | 18 | ||||
| Range | 5-20 | 6-39 | 5-43 | 5-35 | 5-55 | ||||
. | Category . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | 1, Persistently negative . | 2, Fluctuating positive . | 3, Persistently positive . | 4, Relapse . | Total . | ||||
| No. patients | 36 | 51 | 27 | 129 | 243 | ||||
| Patient age, y, median | 35.9 | 32.7 | 36.9 | 34.3 | 34.3 | ||||
| Patient sex | |||||||||
| Female | 13 | 20 | 11 | 60 | 104 | ||||
| Male | 23 | 31 | 16 | 69 | 139 | ||||
| Duration of disease before SCT, y | |||||||||
| Overall | 1.16 | 0.86 | 0.76 | 1.16 | 1.07 | ||||
| Siblings | 0.83 | 0.60 | 0.67 | 0.73 | 0.72 | ||||
| Alternate | 2.1 | 1.80 | 1.6 | 1.7 | 1.69 | ||||
| Disease status at transplantation | |||||||||
| CP | 33 | 39 | 24 | 117 | 213 | ||||
| Advanced | 3 | 12 | 3 | 12 | 30 | ||||
| Donor | |||||||||
| Identical sibling | 24 | 33 | 20 | 52 | 129 | ||||
| Alternative | 12 | 18 | 7 | 77 | 114 | ||||
| GvHD prophylaxis | |||||||||
| Non-TCD | 24 | 31 | 20 | 43 | 114 | ||||
| TCD | 12 | 20 | 7 | 86 | 125 | ||||
| Follow-up, mo | |||||||||
| Range | 21-271 | 15-230 | 20-212 | 16-257 | 15-271 | ||||
| Median duration | 125 | 86 | 54 | 77 | 84.3 | ||||
| PCR determinations/patient | |||||||||
| Median no. | 9 | 14 | 20 | 25 | 18 | ||||
| Range | 5-20 | 6-39 | 5-43 | 5-35 | 5-55 | ||||
SCT indicates stem cell transplantation; and TCD, T-cell depletion.